Analyst Note
| Julie Utterback, CFA |Narrow-moat Baxter beat EPS expectations slightly in the fourth quarter, but its 2021 earnings outlook is a little weaker than we expected. While we may adjust our estimates for 2021 slightly, we do not anticipate materially changing our $73 fair value estimate at first glance. The shares appear about fairly valued.